Day: November 19, 2026

Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic

European Innovation Council funding supports advancement of AT-108, Asgard’s first-in-class off-the-shelf cell reprogramming immunotherapy, toward First-in-Human clinical trialGrant opens the...

ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector

AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads

The two clinical scenarios of ATM loss and SLFN11 loss are found across multiple indications and identify key patient populations...

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research...

Interim Results for the Third Quarter of 2026 – BioPorto reports continued NGAL growth and advances the U.S. Adult Validation Study

November 19, 2026Announcement no. 15             Interim Results for the Third Quarter of 2026 - BioPorto reports continued NGAL growth...

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition...

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing...

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

error: Content is protected !!